However, compared to Ki67 positivity which is a commonly used histopathological marker for disease aggressiveness [30, 31], reduced expression of AnxA6 in tumor tissues appears to be a more reliable tool to assess treatment outcomes for TNBC patients and in particular the tendency for the tumors to relapse following chemotherapy. This evidence concerns the gene MKI67 and neoplasm.